Twenty years after the first FDA approval of kinase inhibitors revolutionized cancer treatment, industry leaders are convening to address persistent challenges and develop next-generation therapeutics. The inaugural Next Generation Kinase Inhibitors Summit will bring together 80+ senior drug developers to tackle issues of drug resistance and safety that currently limit treatment success.
Novel Approaches in Kinase Biology
The summit will showcase groundbreaking research in histidine kinase, phosphatases, and multi-kinases, with presentations from prominent researchers including Tony Hunter from Anavo. These sessions aim to optimize drug specificity and enhance treatment durability, addressing key limitations of existing therapies.
Advanced Profiling Technologies
Leading experts, including renowned researcher Lewis Cantley, will demonstrate how cutting-edge platforms are transforming kinase profiling. Representatives from DeepCure and Kings College London will present new methods for accelerating target selection and predicting off-target effects, streamlining the drug development process.
Breaking Through the Blood-Brain Barrier
A significant focus of the summit will be on innovative drug design strategies to penetrate the blood-brain barrier, particularly crucial for treating brain metastases and neurodegenerative conditions. Researchers from Biogen, Inhibikase, and Black Diamond will present their approaches to optimizing drug potency while achieving better brain penetration.
Personalized Medicine and Resistance Management
Teams from Genentech, AstraZeneca, and Massachusetts Medical School will share insights on utilizing biomarkers for personalized treatment approaches. Their presentations will address strategies for rational combination therapies and methods to combat treatment resistance, aiming to achieve more durable clinical responses.
Tumor Microenvironment Strategies
Experts from TG Therapeutics, Onconova, and AUM Biosciences will discuss optimizing combination strategies by targeting kinase interactions within the tumor microenvironment. These sessions will focus on overcoming resistance mechanisms and improving clinical response rates.
The three-day summit features over 20 speakers and includes a deep-dive workshop, offering unprecedented networking and learning opportunities for professionals in the field. This gathering represents a crucial step forward in developing more effective and durable kinase inhibitor therapies for oncology and beyond.
